2026-01-22 - Analysis Report
**Amgen Inc. (AMGN) Stock Analysis Report**
=============================================

### Company Overview
Amgen Inc. is a multinational biotechnology company specializing in the discovery, development, and delivery of innovative human therapeutics.

### Return Rate Comparison
Comparing the return rate of AMGN (77.83%) with the S&P 500 (91.55%), we observe a cumulative return difference of -13.72%.

### Technical Analysis
#### Moving Averages
*   5-day SMA: $332.80
*   20-day SMA: $330.28
*   60-day SMA: $325.94

The company's recent price fluctuations are relatively stable, with the 20-day and 60-day SMAs trending below the current price.

#### Indicators
*   RSI: 61.26 (neutral)
*   PPO: 0.27 (buy signal)
*   Market Risk Indicator (MRI): 0.80 (medium risk)

The RSI and PPO indicators suggest a neutral to buy signal, while the MRI indicates a moderate level of risk.

#### Recent Events
Recent news articles suggest:
*   Amgen Inc. has announced a high technical and setup rating for potential breakout.
*   Arkadios Wealth Advisors has increased its holdings in Amgen Inc.
*   Amgen has announced an increase in its dividend to $2.52.
*   Amgen has expanded its obesity strategy with Ro collaboration on GLP-1 therapies.

These events could positively impact the company's stock price in the short term.

### Analyst Opinions
Analyst Consensus:
*   Key: Buy
*   Mean rating: 2.41 (~Buy)
*   Opinions: 27
*   Target Price: $331.59 / $425.00 / $180.00

### Recent Earnings Analysis

| Date        | EPS | Revenue      |
|-------------|-----|--------------|
| 2025-11-05  | 5.98 | 9.56 B$     |
| 2025-08-06  | 2.66 | 9.18 B$     |
| 2025-05-02  | 3.22 | 8.15 B$     |
| 2024-10-31 | 5.27 | 8.50 B$     |

The company's earnings have been steadily increasing over the past year, with a notable spike in November 2025. Revenue has also increased, indicating a strong financial performance.

### Financial Information

**Revenue and Profitability**

| Quarter  | Revenue | Profit Margin |
|----------|---------|---------------|
| 2025-09-30 | 9.56B$ | 67.75% |
| 2025-06-30 | 9.18B$ | 67.20% |
| 2025-03-31 | 8.15B$ | 63.58% |
| 2024-12-31 | 9.09B$ | 65.75% |
| 2024-09-30 | 8.50B$ | 61.07% |

**Capital and Profitability**

| Quarter  | Equity | ROE |
|----------|--------|-----|
| 2025-09-30 | 9.62B$ | 33.43% |
| 2025-06-30 | 7.43B$ | 19.28% |
| 2025-03-31 | 6.21B$ | 27.87% |
| 2024-12-31 | 5.88B$ | 10.67% |
| 2024-09-30 | 7.53B$ | 37.60% |

The company's revenue and profit margins have been relatively stable over the past year, with a slight increase in profitability. The Return on Equity (ROE) has also improved significantly.

### Comprehensive Analysis
Based on our analysis of the provided data, we have:

*   A neutral to buy signal from the technical indicators
*   A positive impact from recent news articles
*   Strong financial performance with increasing revenue and earnings
*   Improved profitability and capital structure

Overall, Amgen Inc. appears to be a well-positioned biotechnology company with a strong financial performance and improving indicators. However, it is essential to conduct further research and analysis before making any investment decisions.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.